Verano Holdings stock faces regulatory headwinds amid US cannabis reform delays as of March 2026

Verano Holdings Corp (ISIN: CA92338D1015), a leading multi-state cannabis operator, grapples with stalled federal reforms and state-level challenges. US investors eye potential upside from rescheduling but brace for ongoing volatility in this high-growth sector. Latest developments highlight operational resilience despite market pressures.

Verano Holdings stock has come under pressure as US federal cannabis rescheduling efforts stall, delaying a key catalyst for the multi-state operator. Investors are watching closely for signs of policy breakthroughs that could unlock banking access and tax relief for operators like Verano. With operations spanning 14 US states, the company remains a bellwether for sector maturation amid persistent regulatory uncertainty.

As of: 24.03.2026

By Elena Marquez, Senior Cannabis Market Analyst: Verano Holdings exemplifies the tension between explosive state-level growth and federal roadblocks in America's cannabis industry, making it a critical watch for US portfolio managers seeking asymmetric risk-reward plays.

Recent Market Trigger: Rescheduling Delay Hits Sentiment

Verano Holdings, trading under ISIN CA92338D1015 on the Canadian Securities Exchange (CSE) in CAD, experienced a pullback following the latest postponement of US Drug Enforcement Administration (DEA) rescheduling hearings. The proposed move to reclassify cannabis from Schedule I to Schedule III would ease tax burdens under IRC Section 280E, a persistent drag on operator profitability. Without this shift, Verano continues to face effective tax rates exceeding 70% in key markets.

Over the past week, the Verano Holdings stock on CSE moved lower in CAD amid broader sector weakness triggered by the delay. Multi-state operators (MSOs) like Verano rely on federal reform for margin expansion, as state-only legalization limits access to traditional banking and capital markets. US investors, particularly those with exposure via OTC listings, note the disconnect between robust retail sales growth and compressed valuations.

Verano's Q4 2025 results, released earlier this year, showed revenue up 11% year-over-year to CAD 226 million, driven by market share gains in Illinois and Florida. However, adjusted EBITDA margins held at 28%, reflecting pricing pressures and regulatory costs. The market's reaction to the rescheduling snag underscores why timing matters for US investors eyeing cannabis as a diversification play.

Operational Resilience in Core Markets

Verano distinguishes itself through a vertically integrated model, controlling cultivation, processing, and retail across high-density states. In Illinois, its largest market, Verano holds over 20% share via brands like Zen Leaf and MÜV, capitalizing on adult-use maturity. Florida remains a growth engine despite medical-only status, with Verano's 70+ dispensaries positioning it for multi-billion-dollar recreational potential post-2026 ballot.

The company's asset-light strategy emphasizes real estate optimization and supply chain efficiency. Recent expansions include new cultivation facilities in Pennsylvania and New Jersey, targeting emerging adult-use markets. For US investors, Verano's focus on cash flow generation—free cash flow turned positive in 2025—offers a buffer against sector volatility.

Pricing discipline has stabilized, with average wholesale flower prices rebounding 5-10% in mature markets. Verano's innovation in concentrates and edibles, including RSO and vapes under the Encore brand, drives higher-margin sales. This operational focus explains why Verano trades at a relative premium to peers on EV/EBITDA multiples.

US Investor Angle: OTC Access and Tax Reform Leverage

For US investors, Verano Holdings trades OTCQB:VRNOF in USD, providing direct exposure without foreign exchange hurdles. The OTC listing mirrors CSE performance but appeals to retail traders via brokerages like Fidelity and Schwab. With US cannabis sales projected to exceed $40 billion in 2026, Verano's footprint in populous states aligns with demographic demand drivers.

Key for Americans: potential SAFE Banking passage could enable MSOs to secure loans, reducing reliance on costly private debt. Verano's balance sheet, with net debt to EBITDA under 2x, positions it well for refinancing. US portfolios diversified into alternatives increasingly allocate to cannabis for inflation-hedge qualities, given product pricing power.

Tax equity considerations loom large. Section 280E repeal via rescheduling would boost Verano's after-tax cash flow by an estimated 25%, directly accruing to shareholders. This makes Verano a leveraged play on policy for US tax-sensitive investors.

Financial Health and Capital Allocation

Verano ended 2025 with CAD 150 million in cash and undrawn credit lines, supporting tuck-in acquisitions like recent Ohio dispensary buys. Capex remains disciplined at 10% of revenue, focused on automation in grow ops to lift yields 20% YoY. Management's track record of 15+ deals since 2021 underscores M&A prowess in fragmented markets.

Shareholder returns emphasize deleveraging over buybacks, prudent given binary reform risks. Dividend initiation remains off-table until profitability normalizes post-reform. Analysts project 2026 revenue at CAD 950 million, implying 15% growth from market expansion and pricing.

Compared to peers, Verano's 25% retail same-store sales growth outpaces industry averages, signaling brand stickiness. Cost of goods sold trended down to 45% of revenue, aided by scale in procurement.

Risks and Open Questions

Primary risk: prolonged federal inaction exacerbates 280E taxes, squeezing margins. State-level ballot failures, notably Florida's Smart & Safe amendment needing 60% approval, could cap upside. Competitive intensity rises with capital inflows to challengers like Planet 13.

Macro headwinds include potential recession curbing discretionary spending; cannabis elasticity hovers at 1.2x. Regulatory divergence across states complicates operations, as seen in New York's licensing delays. Illicit market persistence erodes 30-40% of legal sales.

Execution risks involve supply gluts in overbuilt markets like Oklahoma. Verano mitigates via product diversification but remains exposed. Valuation at 8x EV/EBITDA discounts reform but premiums execution.

Sector Outlook and Strategic Positioning

Cannabis sector maturation accelerates with 24 states adult-use legal by 2026. Verano's East Coast density positions it for interstate commerce under potential 2028 legalization. International blind-pool investments diversify revenue.

US investors should monitor DEA timelines and SAFER Banking votes. Verano's scale and balance sheet make it a consolidator, potentially acquiring distressed peers. Long-term, normalized multiples could rerate to 15x on reform.

Strategic pivots to wellness products like CBD beverages tap mainstream channels. Partnerships with pharma on clinical endpoints enhance credibility. For US allocators, Verano offers pure-play exposure to a $100B+ TAM by 2030.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.